ArticleScientific reports2025
Evolutionary trajectory and spread of respiratory syncytial virus group A in neonatal cohorts in Pakistan amidst the COVID-19 pandemic.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Longitudinal Analysis of Respiratory Syncytial Virus in Children during and after COVID-19 Pandemic in China: Shifts in Seasonality and Disease Burden.Journal of epidemiology and global health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A collaborative effort by the National Institute of Health, Pakistan and the World Health Organization initiated RSV surveillance in children under 2 years old in 2019 in Pakistan. This study aimed to characterise RSV disease, assess genetic diversity of circulating subtypes, and reconstruct the evolutionary history and transmission dynamics during the COVID-19 pandemic. Nasal swabs were collected weekly from five sites across three seasons (2019-2022). A subset of samples was sequenced and studied using the BEAST phylodynamic framework. Multivariate logistic regression was performed to explore associations between patient characteristics and infection odds. Out of 758 samples collected, 18.7% tested positive for RSV, mostly RSV-A (93.6%). Influenza A and B positivity rates were 4.2% and 6.3%, respectively. RSV positivity increased from 13% in 2019-2020 to 32.1% in 2020-2021, likely due to the wide spread of respiratory infection and limited implementation of preventive measures. These rates later dropped to 10.0% (2021-22), suggesting a possible re-implementation of such measures. Mutational analysis revealed a unique P376S mutation within the F-4-2 epitopic region of the F gene of one Pakistani virus, which contributes to viral protein oligomerization. The phylodynamic inference revealed predominant circulation of RSV-A over a wider geographical region, reflecting a combination of continual viral entry, with three introductions in 2020, and one each in 2017 and 2018, and one event of persistence across seasons. The observed introductions likely stemmed from Pakistani nationals returning from Europe to their home country. Combined RSV surveillance and phylodynamic modeling effectively uncovers RSV transmission patterns and provides valuable insights for the development and deployment of RSV vaccination and treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.